Biliary tract cancer

The PURITY trial compares giving a three-drug chemotherapy combination before surgery with going straight to surgery in people with biliary tract cancer that can be removed but has a high risk of returning. Participants are adults under 75 with confirmed, non-metastatic biliary t…

This early-phase study tests a personalized mRNA cancer vaccine (XH001) given alongside standard treatment after surgery for people with high-risk solid tumors (bile duct, gallbladder, pancreatic, liver, or stomach cancer). The main goals are to check safety and see if the vaccin…

This early-stage trial is testing a new drug called IDE892, alone or with another drug (IDE397), in people with advanced solid tumors that have a specific genetic deletion (MTAP). The study aims to find safe doses and see if the drugs shrink tumors. It includes 260 adults with ca…

This study is testing a new biologic drug called sacituzumab tirumotecan (MK-2870), alone or with chemotherapy, in people with advanced colorectal, pancreatic, or biliary tract cancers that cannot be removed by surgery. The main goals are to check safety and see if tumors shrink.…

This study tests an experimental oral drug called S241656 (BDTX-4933) in people with advanced solid tumors that have certain genetic changes (KRAS, BRAF, or other RAS/MAPK mutations). The trial has two parts: first, finding a safe dose, then testing how well it works alone or wit…

This study tests a combination of two immunotherapy drugs (iparomlimab and toripalimab) plus bevacizumab and chemotherapy as a first treatment for advanced biliary tract cancer. It involves 32 adults aged 18-75 who have not had prior treatment for their advanced cancer. The goal …

This study tests whether adding the drug zanidatamab to standard chemotherapy (with or without an immunotherapy) can help people with advanced HER2-positive bile duct cancer live longer without their cancer growing. About 286 adults with inoperable or metastatic bile duct cancer …

This study tests a new drug called AZD8205, alone or with another drug (rilvegostomig), in people with advanced solid tumors like breast, ovarian, and lung cancers. The trial has two phases: first to find the safest dose, then to see if it shrinks tumors. About 460 adults whose c…

This trial tests two chemotherapy strategies for people who have had surgery for malignant biliary tract tumors. One group receives hepatic arterial infusion chemotherapy, where drugs are delivered directly to the liver through a catheter. The other group takes capecitabine pills…

This phase II trial is testing whether alternating standard chemotherapy and immunotherapy with a targeted drug called pemigatinib can help people with advanced biliary tract cancers that have FGFR2 alterations. The study includes adults with cancer that cannot be removed by surg…

This Phase 1 trial tests a new drug called BL-M07D1 in 280 adults with advanced HER2-positive cancers, including breast, lung, and stomach cancers. The study aims to find safe doses and check for early signs of tumor shrinkage. Participants must have tried at least two prior trea…

This study tests a new drug called CR-001 in adults with advanced solid tumors that have spread. The goal is to find the safest dose and see if it can shrink tumors. About 290 people will take part in this early-phase trial.

Researchers are testing two investigational radiopharmaceuticals in adults with advanced solid tumors, including colorectal, pancreatic, biliary tract, gastric, esophageal, and head and neck cancers. First, participants receive SKL35502, an imaging agent that highlights tumors ca…

This early-phase trial tests whether adding an experimental drug called CTX-009 to standard chemotherapy (gemcitabine and cisplatin) plus immunotherapy (durvalumab) can safely treat advanced biliary tract cancer that cannot be removed by surgery. About 50 adults will receive the …

This study tests a new drug called AVZO-1418 in people with advanced solid tumors that have spread. The goal is to find a safe dose and see if it shrinks tumors. About 480 adults will take part, receiving the drug alone or with other treatments.

This early-stage study tests a new drug called MK-4884 in about 120 people with advanced or metastatic solid tumors (colorectal, kidney, lung, or bile duct cancer). The main goal is to check the drug's safety and find the right dose. Researchers will monitor side effects and how …

This Phase 2 trial tests an oral drug called BAY 2927088 (sevabertinib) in about 111 adults with advanced solid tumors that have HER2 gene mutations. The drug aims to block the abnormal HER2 protein and stop cancer growth. Participants take a 20 mg tablet daily in 3-week cycles u…

This study tests a drug called tivozanib in people with bile duct cancer that cannot be removed by surgery and has already been treated with chemotherapy. The goal is to find the safest dose and see if the drug can shrink tumors or slow the cancer. Participants take tivozanib by …

This phase 2 trial tests a combination of liposomal irinotecan, fluorouracil, leucovorin, and sintilimab, followed by radiation therapy, as a first-line treatment for people with locally advanced biliary tract cancer that cannot be removed with surgery. About 31 participants will…

This study tests an experimental drug called LBL-024 combined with standard chemotherapy (cisplatin, gemcitabine) and bevacizumab in 140 people with advanced solid tumors. The goal is to see if the combination can shrink tumors and control the disease. Participants must be 18–75,…

This study is testing a drug called patritumab deruxtecan in people with advanced gastrointestinal cancers that have spread. The drug is given through a vein and aims to shrink tumors. The trial will check how safe the drug is and how many people's cancers respond to treatment. A…

This study tests a new drug called ivonescimab against standard chemotherapy (FOLFOX) for people with advanced bile duct cancer that has worsened after initial treatment. About 72 participants who were in the SAFIR-ABC10 trial will be randomly assigned to receive either ivonescim…

This phase II trial is testing whether combining pemigatinib—a drug that targets FGFR2 mutations—with an immunotherapy drug (a PD-1 inhibitor) and possibly chemotherapy can help people with advanced bile duct cancer that has FGFR2 fusions or rearrangements. The study enrolls adul…

This study tests a new drug combination for people with metastatic solid tumors that lack a gene called MTAP. The drugs, BMS-986504 and pemetrexed, aim to stop cancer cells from growing. The trial will check safety and how well the combo works in 72 participants.

This early-phase trial tests an investigational drug called ABBV-400 in about 300 adults with advanced solid tumors, including liver, pancreatic, breast, and ovarian cancers. The study aims to see if the drug can shrink tumors and to check for side effects. Participants receive A…

This global Phase 3 trial is testing whether adding the experimental immunotherapy rilvegostomig to standard chemotherapy helps people with advanced biliary tract cancer live longer, compared to adding the approved drug durvalumab. About 1,100 participants with inoperable or meta…

This early-phase study tests a new drug, LNCB74, in people with advanced solid tumors (ovarian, breast, endometrial, bile duct, or lung cancer) that have not responded to standard treatments. The drug is designed to deliver a cancer-killing agent directly to tumor cells. The main…

This study tests whether a new drug combination (trastuzumab deruxtecan plus rilvegostomig) works better than standard chemotherapy for people with advanced bile duct cancer that has a specific protein called HER2. About 620 adults with untreated, advanced HER2-positive bile duct…

This phase 2 trial tests whether alternating between two chemotherapy regimens (mFOLFOX and mFOLFIRI) works better than using just one (mFOLFOX) as a second-line treatment for advanced biliary tract cancer. The study will enroll 130 adults whose cancer has progressed after first-…

This early-stage trial is testing an experimental vaccine called YMN-136 in people with advanced liver, pancreatic, or biliary tract cancer that has progressed after standard treatment. The main goal is to check the vaccine's safety and find the best dose, while also seeing if it…

This phase 2 trial is testing a drug called datopotamab deruxtecan (Dato-DXd), alone or with other cancer medicines, in people with advanced or metastatic solid tumours. The study includes seven cancer types and aims to see if the drug shrinks tumours and how safe it is. Around 4…

This early-stage trial is testing an experimental immunotherapy called AB122, given alone or combined with other investigational drugs, in people with advanced solid tumors such as pancreatic, colorectal, lung, and stomach cancers. The goal is to find out which combinations are s…

This study tests whether adding an experimental drug (D07001) to standard chemotherapy (capecitabine) helps people with advanced bile duct cancer live longer. About 195 adults whose cancer has not responded to earlier treatments will receive either D07001 or a placebo, plus capec…

This study tests a new drug called AZD0901, alone or with other cancer treatments, in people with advanced solid tumors that have a specific protein called CLDN18.2. The goal is to see if the drug is safe and can shrink tumors. About 224 adults with stomach, pancreatic, or bile d…

This trial tests whether adding an experimental immune therapy (QL1706) to standard chemotherapy can shrink tumors in people with advanced biliary tract cancer that has a specific marker (PD-L1 positive). About 38 participants will receive the combination every three weeks for up…

This Phase 2 trial is testing two experimental drugs (SSGJ-705 and SSGJ-612) with or without chemotherapy in 150 adults with advanced HER2-positive solid tumors, including colorectal, bladder, breast, bile duct, and stomach cancers. The goal is to see if the combination can shrin…

This Phase 3 trial tests a new drug, BL-M07D1, against standard chemotherapy in about 400 people with a specific type of advanced bile duct cancer (HER2-positive) that has stopped responding to platinum-based chemo. The goal is to see if BL-M07D1 can help people live longer. Part…

This Phase 3 trial tests a new drug called BL-B01D1 against standard chemotherapy in 538 people with advanced biliary tract cancer that has worsened after prior treatments. The goal is to see if the new drug helps people live longer. The study is not yet recruiting.

This phase II trial is testing whether freezing tumors (cryoablation) before giving an experimental immunotherapy drug called rilafup α along with standard chemotherapy can help shrink or control advanced bile duct and gallbladder cancers. The study enrolls 30 people who have not…

This phase 3 trial tests whether a combination of two experimental drugs (futibatinib and zimberelimab) plus standard chemotherapy can help people with advanced biliary tract cancer live longer compared to current standard immunotherapy combinations. The study enrolls about 784 a…

This trial tests whether giving the immunotherapy drug durvalumab along with chemotherapy before surgery can shrink biliary tract cancers and improve outcomes. About 40 people with resectable tumors will receive the combination, then undergo surgery. The goal is to see if this ap…

This early-phase trial tests an experimental drug called YH32367 in people with HER2-positive solid tumors that have spread or cannot be removed by surgery. The study has two parts: first, finding a safe dose, then testing that dose in specific cancer types like biliary tract can…

This phase 2 trial tests whether a combination of three drugs—trastuzumab rezetecan, adebrelimab, and lenvatinib—can shrink tumors or slow disease progression in people with advanced biliary tract cancer (including bile duct and gallbladder cancers) that has grown despite prior t…

This early-phase trial is testing a combination of three treatments for people with advanced biliary tract cancer that cannot be surgically removed. The approach delivers chemotherapy directly to the liver, along with an immunotherapy drug and a targeted therapy pill. The study a…

This study looks at two types of metal stents (partially covered vs. bare) used to open blocked bile ducts in people with incurable cancer. The goal is to see which stent keeps the duct open longer and causes fewer problems. Sixty adults who already have a drainage tube will be r…

This study tests a new drug called Spevatamig (PT886) in people with advanced stomach, pancreatic, or bile duct cancers that have spread or cannot be removed by surgery. The drug is a type of antibody that targets two proteins on cancer cells to help the immune system attack them…

This study tests whether adding a targeted, tumor-destroying treatment (like focused radiation or heat ablation) can help people with certain gastrointestinal cancers—such as colorectal, small bowel, or pancreatic cancer—continue their current systemic therapy longer when only a …

This phase II trial tests whether a combination of durvalumab (an immunotherapy), chemotherapy (GEMOX or GC), followed by lenvatinib (a targeted therapy) can prevent biliary tract cancer from coming back after surgery. About 222 adults with bile duct or gallbladder cancer will be…

This phase 3 trial tests a new drug called nanvuranlat in 480 adults with advanced biliary tract cancer that has worsened after prior treatment. Participants receive either nanvuranlat or one of several standard treatments. The main goal is to see if nanvuranlat helps people live…

This phase II trial is testing a combination of three drugs—trastuzumab rezetecan, adebrelimab, and lenvatinib—as a first treatment for people with advanced or metastatic biliary tract cancer that has HER2 markers. The study aims to see how well the drugs shrink tumors and contro…

This study tests a new combination of an immunotherapy drug (adebrelimab) plus two chemotherapy drugs (gemcitabine and nab-paclitaxel) as a first treatment for people with biliary tract cancer that cannot be removed by surgery. The goal is to see if this combo can shrink tumors a…

This study tests an experimental drug called YH32364 in adults with advanced solid tumors that have high levels of EGFR and have not responded to previous treatments. The trial has two parts: first, finding a safe dose in about 30 people, then testing that dose in 50 people with …

This study tests a new therapy called EB-HC01, which uses specially engineered natural killer (NK) immune cells to attack cancer cells that have two specific markers (HER2 and CEACAM5). The trial enrolls adults with advanced bile duct or gallbladder cancers that have worsened aft…

This study looks at whether getting standard immunotherapy in the morning (before 11 am) or afternoon (after 12 pm) changes how well it fights advanced or metastatic solid tumors. Researchers think the body's internal clock (circadian rhythm) might affect immune activity. About 1…

This study tests a new drug called INV-8989 in people with advanced solid tumors that have a specific genetic change called KRAS G12D. The trial has two phases: the first finds the safest dose, and the second checks how well the drug shrinks tumors. About 178 adults with cancers …

This study tests a new drug, MP0317, combined with standard chemotherapy and immunotherapy for people with advanced bile duct cancer that cannot be removed by surgery. The goal is to see if this combination helps keep the cancer from growing for at least 12 months. About 75 adult…

This early-phase trial tests an experimental oral drug called ST-01156 in adults with advanced solid tumors that have spread or cannot be removed by surgery. The drug works by breaking down a protein inside cancer cells. The main goals are to find a safe dose and check for side e…

This early-phase study tests a new cell therapy for people with advanced biliary tract cancer (bile duct or gallbladder cancer) that has not responded to standard treatments. The therapy uses the patient's own immune T cells, enhanced with a protein called CD160 to better target …

This study tests two surgical techniques for bile duct cancer that has spread to nearby lymph nodes. One method removes the bile duct completely to take out all affected lymph nodes, while the other leaves the bile duct in place but may leave some lymph tissue behind. The goal is…

This early-phase trial tests a new cell therapy called UCLH80-1 in 36 people with advanced solid tumors (colorectal, gastric, pancreatic, and bile duct cancers) that have not responded to standard treatments. The therapy uses specially engineered immune cells to target a protein …

This phase 3 trial is testing whether giving a targeted therapy after initial standard chemotherapy can help people with advanced biliary cancer live longer without their disease getting worse. Participants must have a tumor with a specific genetic change and stable disease after…

This study is testing a treatment strategy for biliary tract cancer, a group of aggressive cancers with poor survival. The approach combines hepatic arterial infusion chemotherapy (HAIC) with systemic drugs like bevacizumab and an immunotherapy. The goal is to shrink tumors and i…

This early-phase study tests a personalized peptide vaccine (mBTCvax) combined with two immunotherapy drugs (durvalumab and tremelimumab) in 25 adults with advanced biliary tract cancer. The goal is to see if the combination is safe and can boost the immune system's ability to ta…

This early-phase study tests a new drug called IBI343 in people with advanced solid tumors that cannot be removed by surgery or have spread. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. About 470 participants will take part in mul…

This study tests a new drug called MDX2001 in people with advanced solid tumors that have spread. The main goals are to check the drug's safety and see if it can shrink tumors. About 285 adults with various cancers like lung, breast, or colon cancer will take part. This is an ear…

This study tests a new way to treat bile duct cancer that cannot be removed by surgery. It combines chemotherapy given directly into the liver with standard IV chemo, plus two additional drugs (adebrelimab and apatinib) that boost the immune system and block tumor growth. The tri…

This phase 2 trial is testing whether adding an experimental immunotherapy drug called ZG005 to standard chemotherapy (gemcitabine and cisplatin) can help people with advanced gallbladder cancer. About 60 participants will receive either the combination or standard treatment. The…

This early-phase study tests a new drug called IMC-002 in about 62 adults with advanced solid tumors that no longer respond to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can help control the cancer. Participants receive t…

This study tests a new combination of drugs (iparomlimab, tuvonralimab, chemotherapy, and lenvatinib) as a second-line treatment for people with advanced bile duct cancer that has worsened after first-line therapy. The goal is to see if this approach can help control the cancer a…

This phase IIa trial is testing two experimental drugs, HX009 and IN10018, given together with or without standard chemotherapy, in 124 adults with advanced solid tumors, specifically biliary tract cancer and melanoma. The study aims to find the best dose and see if the combinati…

This study tests an experimental drug called TQB2102 in people with advanced bile duct cancer that has a specific marker (HER2-positive). The goal is to see if the drug can shrink tumors or slow the cancer's growth. About 102 adults aged 18 to 75 with good organ function are bein…

This early-phase trial is testing a new antibody drug called ZM008, first by itself and then together with another drug (toripalimab), in people with advanced solid tumors like lung, head and neck, and pancreatic cancers. The study aims to find a safe dose and see if the combinat…

This early-phase trial tests a new drug called emavusertib added to standard chemotherapy and immunotherapy for people with untreated advanced bile duct cancer. The goal is to see if the combination is safe and to find the best dose. About 48 participants will be enrolled.

This study tests a genetically modified herpes virus (RP2) that infects and destroys cancer cells while also stimulating the immune system. It is given alone or together with standard drugs (bevacizumab, atezolizumab, or durvalumab) to 60 adults with advanced liver or bile duct c…

This study tests a combination of three drugs (trastuzumab, serplulimab, and chemotherapy) in 20 adults with advanced bile duct or bladder cancers that have stopped responding to standard treatments. The goal is to see if this approach can shrink tumors and improve survival. Part…

This study tests an experimental drug called SHR-A1904 in people with advanced biliary tract cancer (bile duct cancer) that has not responded to previous treatments. The drug targets a protein called CLDN18.2 found on some cancer cells. The trial aims to see if the drug can shrin…

This study tests a new drug (CDX-1140) combined with three other cancer drugs for people with advanced biliary tract cancer that has spread or come back after treatment. About 60 adults will receive the drugs through an IV and a pill over 21-day cycles for up to 2 years. The goal…

This study tests a new combination of four drugs—two standard chemotherapies plus an immunotherapy and a cholesterol drug—in people with advanced bile duct cancer. All 29 participants will receive the same treatment. Researchers will check how many patients see their tumors shrin…

This early-stage study tests an experimental drug called TJ033721 (givastomig) in people with advanced or metastatic solid tumors that have stopped responding to standard treatments. The main goals are to check the drug's safety, find the right dose, and see how the body processe…

This study tests two experimental drugs, AK130 and AK112, in people with advanced biliary tract cancer (a type of bile duct cancer). The first part finds a safe dose; the second part checks if the combination shrinks tumors. About 135 participants will take part.

This phase 2 trial is testing whether a combination of two immune-boosting drugs, ligufalimab and cadonilimab, can shrink advanced liver or bile duct cancers that have stopped responding to prior treatments. About 64 adults will receive the drugs by IV every three weeks. The main…

This study looks at the safety of the drug Tasfygo in 60 people with advanced biliary tract cancer that has a specific gene change (FGFR2 fusion) and has gotten worse after chemotherapy. Researchers will track side effects and how well the drug works. The goal is to make sure the…

This phase II trial is testing a combination of two chemotherapy drugs—trifluridine/tipiracil (pills) and oxaliplatin (IV)—in people with advanced or metastatic biliary tract cancer whose first treatment stopped working. The goal is to see if this combo can control the cancer bet…

This study tests whether giving an antibiotic (gentamicin) directly into the bile duct during a procedure called ERCP helps people with acute cholangitis recover faster. About 172 adults with mild to moderate infection will be randomly assigned to receive either the extra antibio…

This phase 2 trial is testing a new approach for people with advanced bile duct cancer that has caused a blockage. The treatment combines a light-activated drug (sodium porphyrin) with standard chemotherapy (gemcitabine and cisplatin). The goal is to see if this combination can h…

This study tests a personalized mRNA vaccine called iNeo-Vac-R01 for people with biliary cancer who have had surgery to remove their tumor. The vaccine is designed to train the immune system to attack cancer cells based on each patient's unique tumor markers. The main goal is to …

This study tests a new combination of drugs (SHR-8068, adebrelimab, and chemotherapy) against the current standard treatment for advanced bile duct cancer. About 604 people with inoperable cancer who haven't had prior treatment will take part. The goal is to see if the new combo …

This phase 2 trial is testing a combination of four drugs—two chemotherapy drugs (gemcitabine and oxaliplatin), a targeted therapy (donafenib), and an immunotherapy (tislelizumab)—in 93 people with advanced biliary tract cancer that has spread. The goal is to see if this mix can …

This study tests a precision medicine approach for people with advanced biliary tract cancer that has a specific IDH1 gene mutation and has stopped responding to standard chemotherapy. About 300 participants will receive a combination of ivosidenib (a targeted pill) plus either l…

This early-phase trial tests a new drug called MT-4561 in about 27 people with advanced solid tumors (like lung, breast, or pancreatic cancer) who have no standard options left. The main goals are to find a safe dose and see if the drug can shrink tumors. It is a first-in-human s…

This phase 2 trial is testing whether adding the immunotherapy drug pembrolizumab to standard chemotherapy or the targeted drug lenvatinib can help people with advanced biliary tract cancer live longer and control their tumors better. The study will enroll 60 adults whose cancer …

This early-phase study tests whether adding heat therapy and a special type of radiation to standard chemoimmunotherapy is safe and feasible for people with advanced bile duct cancer that cannot be removed by surgery. About 15 participants will receive the combination treatment. …

This phase 2 trial is testing whether adding two immunotherapy drugs (tuvonralimab and iparomlimab) to standard chemotherapy before surgery can improve outcomes for people with bile duct or gallbladder cancer. About 45 adults with resectable or borderline-resectable cancer will r…

This study tests whether giving a mix of two chemotherapy drugs (gemcitabine and cisplatin) plus an immunotherapy drug (pembrolizumab) before and after surgery is safe and helps shrink tumors in people with biliary tract cancer. About 27 adults with resectable cancer will take pa…

This study tests a combination of four drugs—gemcitabine, cisplatin, nab-paclitaxel, and tislelizumab—in people with advanced biliary tract cancer (bile duct or gallbladder cancer) that has not been treated before. The goal is to see if this mix can shrink tumors and improve surv…

This study is testing whether a quick lab test called MiniPDX can help doctors choose the best chemotherapy drugs for people with bile duct cancer after surgery. The test measures how sensitive a patient's tumor cells are to different drugs in just 7 days. Researchers will follow…

This study explores whether a common blood test that measures how well blood clots (called TEG) can also act as a biomarker for cancer. Researchers will compare TEG results from patients with several types of cancer (liver, pancreas, bile duct, esophagus, colorectal, and lung) ag…

This study is testing a blood test that looks for DNA changes from tumors to help diagnose and manage biliary tract cancers, which are often found late and have a low survival rate. Researchers will enroll 1,800 participants with confirmed cancers to see how accurate the test is.…

This study compares two types of nerve blocks—coeliac plexus block and splanchnic nerve block—to see which one reduces pain better in adults with upper abdominal cancer. Forty-four participants will receive one of the procedures and be monitored for pain, opioid use, and quality …

This trial tests a supportive web-based app for people with advanced pancreatic, biliary tract, or non-small cell lung cancer who are about to start their first line of chemotherapy. Each week, participants answer questions about their symptoms using the app. If their answers sug…

This study tests whether olanzapine, a drug already used for other conditions, can help cancer patients who are losing weight and appetite. About 66 adults with advanced lung, stomach, or bowel cancers will receive either olanzapine or a placebo. The goal is to see if olanzapine …

This early-stage trial tests a new drug called GB18 in 18-36 cancer patients who are losing weight and appetite due to their illness (cachexia). The drug is given as a shot under the skin. The main goal is to check safety, but researchers will also see if it helps patients gain w…

This study compares giving cancer treatment at home versus in the clinic for people with advanced cancers. The goal is to see if home treatment reduces stress, financial burden, and improves overall experience. About 220 participants will be randomly assigned to receive their reg…

This study tests a new type of stent designed to drain bile from the liver in patients whose bile ducts are blocked by cancer. The stent is placed using an endoscope guided by ultrasound, without major surgery. The goal is to see if the stent is safe and works well in 20 adults w…

This study tests whether using virtual reality (VR) can reduce severe belly pain and improve quality of life in people with digestive tract cancers. 360 participants will be split into three groups: one using a skills-based VR program, one using distracting VR videos, and a contr…

This study is for people with advanced bile duct or pancreatic cancer who have significant pain. Researchers want to see if adding a nerve-blocking pain treatment (celiac plexus block) to standard first-line cancer therapy helps control pain and shrink tumors better than standard…

This study compares three routine pain control methods used during minimally invasive cancer surgery: a nerve block plus local anesthetic, nerve block alone, or local anesthetic alone. About 48 adults having surgery for various cancers will be randomly assigned to one of the thre…

This study will follow about 4,490 adults with liver or bile duct cancer who are receiving durvalumab-based treatment as part of their routine care. Researchers want to see how long patients live and how well the treatment works outside of clinical trials. The goal is to gather r…

This study looks at tumor samples from 2,100 Chinese patients with lung, gynecologic, bile duct, or bladder cancers. Researchers will compare different HER2 testing methods to see how well they agree with each other. The goal is to improve the accuracy of HER2 testing, which help…

This study creates a registry of up to 4000 people with primary liver cancer (hepatocellular carcinoma or biliary tract cancer) treated at San Raffaele Hospital. Researchers will collect medical records and, for some participants, biological samples to search for new biomarkers t…

This study explores whether a blood test that detects circulating tumor DNA (ctDNA) can help doctors personalize treatment for people with five types of advanced cancer: non-small cell lung cancer, gastrointestinal stromal tumors, colorectal cancer, biliary tract cancer, and ovar…

This study tests whether personalized nutrition plans can improve recovery after Whipple surgery for pancreatic, bile duct, or ampullary cancers. Twenty patients in Pakistan will receive tailored meals and supplements before and after surgery, and be followed for 6 months. Resear…

This study is collecting tissue and fluid samples from 160 people with suspected liver, bile duct, or pancreatic cancers. Researchers want to understand these cancers better and test new imaging and sampling tools for earlier, more accurate diagnosis. The study does not test a ne…

This study is testing whether a blood test that looks for tumor DNA (ctDNA) can be as good as a tissue biopsy for finding genetic changes in advanced bile duct cancer. Researchers will enroll 200 adults with advanced biliary tract cancer across multiple hospitals in Korea. The go…

This study enrolls 100 adults with advanced biliary tract cancer who are already scheduled to receive a combination of two drugs (lenvatinib and pembrolizumab). Researchers will collect blood and tumor samples to look for genetic markers that might predict who responds best to tr…

This study is testing whether a blood test that looks for tumor DNA (ctDNA) can find genetic changes in advanced bile duct cancer as well as a traditional tissue biopsy. The goal is to make it easier and less invasive to identify which patients might benefit from targeted therapi…

This study aims to find out if certain Helicobacter bacteria (like H. pylori) are more common in people with biliary tract cancer than in those with non-cancerous gallbladder issues. Researchers will test tissue samples from 250 participants, including cancer patients, people wit…

This study collects and stores tissue and blood samples from people with stomach, esophageal, pancreatic, liver, and other gastrointestinal cancers. The goal is to build a large database of samples and medical information to help researchers understand these cancers better. Parti…

This study is testing whether measuring ctDNA (bits of tumor DNA) in blood or stool can help doctors manage patients with cancers of the digestive tract, including pancreas, colon, and bile duct cancers. Researchers will track survival and see how these markers relate to outcomes…